Dear Erowid Readers: We're a small nonprofit that runs the top drug information website in the world. We have only 4 staff but serve 12 million users, and have costs like any big website: servers, power, office space, programs, and staff. To protect our independence, we don't run ads or take government funds. If everyone reading this gave $3, our fundraising would be done today. If Erowid is useful to you, take a minute to keep it online and ad-free another year!
Donate by Bitcoin

Erowid References Database

Gallimberti L, Schifano F, Forza G, Miconi L, Ferrara SD. 
“Clinical efficacy of gamma-hydroxybutyric acid in treatment of opiate withdrawal”. 
Eur Arch Psychiatry Clin Neurosci. 1994;244(3):113-4.
This paper describes the role of gamma-hydroxybutyric acid (GHB) in the treatment of opiate withdrawal syndrome. In the two patients described, after having abruptly withdrawn from long-term methadone treatment, GHB was orally administered (each dose given every 4-6 h) for 8-9 days. The GHB showed both a high efficacy (some mild and transient symptoms attributable to opiate withdrawal were observed, but only in the first days of therapy) and a good tolerability (no clinical phenomena interpreted as GHB side effects were found). These results could be of interest in improving the pharmacological treatment of drug addiction.
Submit Comment
[ Cite HTML ] Plants & Drugs Mind & Spirit Freedom & Law Arts & Sciences Search About Erowid and Feedback Library & Bookstore Copyrights Memberships noref